| Symbol | CURX |
|---|---|
| Name | CURANEX PHARMACEUTICALS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 2 JERICHO PLAZA,SUITE 101B, JERICHO, New York, 11753, United States |
| Telephone | 718-673-6078 |
| Fax | — |
| — | |
| Website | www.curanexpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0002025942 |
| Description | Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Additional info from NASDAQ: |
New Form S-8 - Curanex Pharmaceuticals Inc <b>Filed:</b> 2026-07-21 <b>AccNo:</b> 0001493152-26-034091 <b>Size:</b> 456 KB
Read moreNew Form DEF 14C - Curanex Pharmaceuticals Inc <b>Filed:</b> 2026-06-29 <b>AccNo:</b> 0001493152-26-030447 <b>Size:</b> 319 KB
Read moreWolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)
Read moreWolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)
Read more(70% Positive) CURANEX PHARMACEUTICALS INC (CURX) Announces Clinical Development Update
Read moreCuranex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission
Read moreWolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)
Read more(99% Neutral) CURANEX PHARMACEUTICALS INC (CURX) Announces Update on Collaboration with Curanex Pharmaceuticals Inc Nevada
Read moreRosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX
Read moreRosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07739017 | OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma | Phase1 | Recurrent Glioblastoma | Not_Yet_Recruiting | 2026-12-01 | 2028-09-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| CT-179 | Other | Phase PHASE1 | Recurrent Glioblastoma | NOT_YET_RECRUITING | NCT07739017 |